Home LiteratureArticle Details
PMID: 23063760 Published · ppublish English Journal Article

Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.

Gynecologic oncology ·Vol. 128 ·No. 1 ·2013-01-00 ·Pages 54-59

Shim SH, Lee SW, Park JY, Kim YS, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH

Abstract

To develop a nomogram for predicting the probability of 5year survival after definitive concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). Between 1998 and 2008, 209 patients with LACC were treated with definitive CCRT. Multivariate analysis using Cox proportional hazards regression model was performed. A nomogram based on this Cox model was developed and internally validated by bootstrapping. Its performance was assessed by using the concordance index and a calibration curve. The median age was 55years (range, 26-78). Of the patients, 9, 16, 129, 3, 42 and 10 had FIGO stage IB2, IIA, IIB, IIIA, IIIB, and IVA disease, respectively. Histology revealed that 190, 13, 4, and 2 patients had squamous, adenocarcinoma, adenosquamous, and small cell cervical cancer, respectively. In 91 patients, PET/CT was performed before CCRT. The median follow-up period was 51months (range, 6-151) and there were 50 (23.9%) disease-related deaths. Multivariate regression analysis revealed that histology, tumor size, and paraaortic lymph node metastasis (defined by MRI), but not PET/CT before CCRT, were independent predictors of overall survival. A nomogram for predicting the 5year survival incorporating these three significant variables was constructed. The concordance index was 0.69. The predictive ability of the nomogram proved to be superior to that of the FIGO staging system (p<0.05). The nomogram was a better predictive model for overall survival than the FIGO staging system. If externally validated, it could be used to counsel patients with LACC who must choose additional treatment modalities after definitive CCRT.

MeSH Terms
Adult Aged Chemoradiotherapy Female Humans Middle Aged Multimodal Imaging Neoplasm Staging Positron-Emission Tomography Proportional Hazards Models Reproducibility of Results Risk Assessment Survival Rate Tomography, X-Ray Computed Uterine Cervical Neoplasms/diagnostic imaging,mortality,pathology,therapy
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Shim Seung-Hyuk
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Lee Shin-Wha
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Park Jeong-Yeol
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim Young Seok
Department of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim Dae-Yeon
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim Jong-Hyeok
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim Yong-Man
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Kim Young-Tak
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Nam Joo-Hyun
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: jhnam@amc.seoul.kr.
Article Info
Journal
Gynecologic oncology
Abbr.
Gynecol Oncol
ISSN
1095-6859
Published
2013-01-00
Epub
2012-00-09
Pages
54-59
Language
English
Region
United States
NLM ID
0365304
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com